Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’

Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’
Kasia Mulligan, Spokesperson for the Patients Come First — Provided photo
0Comments

Kasia Mulligan, national spokesperson for Patients Come First, said the 340B rebate pilot program introduces oversight and ensures drug savings directly benefit patients. The statement was made in an op-ed.

“The lack of transparency and accountability measures in the current discount model has enabled hospitals to pocket the discounts, intended for patients, and divert the savings to fund unrelated projects, such as infrastructure improvement,” said Mulligan. “So much that 83 percent of people support reforming the program to ensure those savings reach the patients who need them most. This rebate model provides the oversight that 340B has needed for decades, and nearly 80 percent of people agree it’s a powerful change to the status quo. Participating pharmaceutical companies are taking steps toward greater transparency, aiming to improve the patient healthcare experience and ensure cost savings reach those patients.”

Established in 1992 and administered by the Health Resources and Services Administration (HRSA), the 340B Drug Pricing Program was created to help healthcare providers stretch limited resources to serve vulnerable populations. It allows eligible entities to purchase outpatient drugs at reduced prices. These savings are intended to support access to care for low-income and uninsured patients.

A 2024 report by the National Alliance of Healthcare Purchaser Coalitions found that prices at large 340B hospitals were 35% higher on average for common outpatient services compared to non-340B hospitals. The study estimated that this pricing difference results in an added $36 billion annually in healthcare costs for employers. These findings were based on an analysis of commercial claims data from over 25 million American workers and their families.

PhRMA reported that California’s 340B program has seen significant growth, with hospitals maintaining over 3,500 contracts with pharmacies as of 2025. Approximately 40% of these involve out-of-state pharmacies, sparking discussions about whether such arrangements align with the program’s original intent to serve vulnerable communities.

Kasia Mulligan is the national spokesperson for the consumer patient advocacy group, Patients Come First. The organization advocates for greater transparency, accountability, and patient-focused reforms in healthcare policy. Mulligan represents the group in public statements and written commentary on health system issues.



Related

Heather K. McDevitt Chair

White & Case advises National Taxi on sale to Dubai Taxi Company

White & Case LLP has advised National Taxi LLC on its sale to Dubai Taxi Company PJSC for about US$400 million. The acquisition will give DTC full ownership of National Taxi pending regulatory approval. This move strengthens DTC’s presence across major cities in the UAE.

Patti Poppe, Chief Executive Officer at Pacific Gas and Electric Company (PG&E)

PG&E urges California graduates to secure metallic balloons during celebrations

PG&E is urging graduates in California to secure helium-filled metallic balloons during celebrations. The company warns that loose balloons can cause significant power outages if they contact overhead electrical lines.

Joe Conroy Partner and Chairman

Iridium Communications announces agreement to acquire Aireon LLC

Iridium Communications has agreed to acquire Aireon LLC as announced on May 15. Cooley LLP served as legal advisor for Iridium during this transaction.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Golden State Today.